Introduction: Autophagy in Adipocytes
=====================================

Autophagy
---------

Macroautophagy, generally referred to as autophagy, is a cytosolic degradation and recycling process of damaged organelles and unwanted components in the cell ([@B77]; [@B99]; [@B15]). When the cells or tissues are limited in their nutrient supply or exposed to a substantial amount of environmental, oxidative, or genotoxic stresses, autophagy as a cellular survival and defense mechanism can be activated ([@B99]; [@B14]; [@B18]; [@B15]). Autophagy can be induced in the cell through inhibition of either the nutrient-sensing kinase, mechanistic target of rapamycin complex 1 (mTORC1), or the activating-stress-sensing kinase, 5′-AMP activated protein kinase (AMPK) ([@B35]; [@B37]; [@B80]). On the other hand, when cells or tissues are supplied with excessive nutrients, the autophagy process is not necessary and is attenuated through mTORC1 activation and AMPK inhibition ([@B35]; [@B37]; [@B80]). When autophagy is suppressed for an extended period of time from continuous overnutrition, as with a high fat and/or fructose diet, the accumulation of unwanted proteins and organelles in the major metabolic tissues -- such as adipose, liver, muscle, and pancreas -- can become detrimental and eventually induce metabolic dysfunction and diseases such as obesity and diabetes ([@B99]; [@B14]; [@B68]). However, contradictory to findings of previous studies, autophagy seems hyperactivated in an effort to generate more fats from recycled energy in adipose tissues of obese patients ([@B41]; [@B33]). A few reports suggest that autophagy inhibition can be a protective mechanism against high-fat diet-induced metabolic dysfunction by converting white adipose tissue (WAT) to brown adipose tissue (BAT) ([@B6]; [@B62]). Throughout the last decade, the therapeutics of modulating autophagy activity have drawn much attention; however, their clinical effectiveness in improving the metabolic profiles of humans with adipocyte metabolic dysfunctions linked to overweight, obesity, and diabetes has not been ascertained ([@B74]; [@B25]).

Adipogenesis
------------

Adipogenesis is a unique adipocyte differentiation process that generates lipid droplets with triglycerides and fatty acids inside the lipid vacuoles ([@B69]; [@B67]; [@B2]). Autophagy for non-selective bulk degradation of proteins and lipids through the fusion of autophagosomes and lysosomes is suggested as one of the major types of autophagy in adipocytes ([@B77]; [@B75]; [@B67]). The relationship between adipogenesis and autophagy has drawn much attention over the past decade regarding the potential link to metabolic diseases such as obesity. Autophagy is necessary and activated when white adipocyte undergoes differentiation ([@B77]; [@B75]; [@B99]; [@B2]). Chloroquine treatment and autophagy-related protein (ATG) 5 knockdown decreases adipogenesis of mouse embryonic fibroblast (MEF) cells. Targeted deletion of ATG5 in mice leads to a dramatically reduced mass of Perilipin A-positive white adipocytes in late-stage embryos and neonatal pups ([@B9]; [@B77]). Singh et al. and other research groups also observed decreased levels of microtubule-associated protein 1A/1B-light chain 3 (LC3), peroxisome proliferator-activated receptor (PPAR)- γ, and triglyceride. This finding indicates that adipocyte differentiation and lipid accumulation are blocked by inhibition of autophagy when ATG7 is knocked down in adipocytes or in adipose-specific deletion in mice ([@B77]; [@B98]; [@B75]). When ULK1, the mammalian homolog of ATG1 and the downstream autophagy kinase target of mTORC1, is knocked down in 3T3-L1 white adipocytes, adipogenesis increases, although autophagy is inhibited. However, the ULK2 knockdown in white adipocytes blocks both autophagy and adipogenesis ([@B67]). An increase in autophagy has been reported in adipose tissues derived from obese humans and mice, supporting adipogenesis in forming and storing more fat depots in the face of overnutrition ([@B41]; [@B22]; [@B40]). Both an increased level of the lipidated form of LC3 (LC3-II) as an autophagosome marker and a decreased level of ubiquitin-binding scaffold protein p62, also called sequestosome 1(SQSTM1), were observed in obese humans and mice, the combination of which would appear to be consistent with an increase in autophagy activity during adipogenesis ([@B39]; [@B94]). The level of autophagy activity seems to differ or at least to fluctuate depending on the adipose tissue type, external stimuli, and tissue age ([@B14]; [@B40]; [@B51]). Autophagy is activated when white adipocyte is undergoing differentiation to form lipid droplets. However, in an opposite way, autophagy also can be inhibited when brown adipocyte is activated with UCP1 and PPAR-γ, increasing thermogenesis and browning, respectively, under cold exposure ([@B75]; [@B15]; [@B24]). Based on previous studies on autophagy in different types of adipocytes, the inhibition of autophagy seems to be better for obesity prevention by reducing the formation of lipid droplets in white adipocytes and promoting energy expenditure in beige or brown adipocytes ([@B77]; [@B41]; [@B67]; [@B15]).

Adipocytes
----------

Adipocytes are the main type of cells found in both white and brown adipose tissues ([@B54]). White adipocytes contain a single lipid droplet and a small number of mitochondria. Brown adipocytes contain multiple small lipid droplets, enriched amounts of mitochondria, and exhibit a unique thermogenesis function through uncoupling protein 1 (UCP1). Beige adipocytes are the brown-like cells located within WAT, and they have a higher expression level of UCP1 than white adipocytes ([@B91]; [@B54]; [@B6]; [@B22]). Browning is a process of dynamic conversion or modification of white adipocytes into beige/brown adipocytes upon activation by exposure to physiological, pharmacological, or hormonal stimuli ([@B92]; [@B1]). Browning of white adipocytes is generally induced under cold exposure and exercise ([@B91]; [@B54]; [@B3]). However, this process does not completely transform or transdifferentiate white adipocytes into brown adipocytes. The white adipocytes become only a brown adipocyte-like phenotype, which is also called beige, inducible brown, brown-in-white, or brite adipocyte ([@B10]; [@B71]). In mouse studies, more beige cells have been detected in WAT of lean, compared to obese mice ([@B66]). However in human studies, they only observed higher native BAT activity but not active beige cells in lean subjects ([@B85]). Conventional methods to increase UCP1 in beige/brown fat cells, such as cold acclimation in humans, have not revealed any inducible browning fat depots in addition to the constitutively present depots and have not also proven enough to mediate browning of white fat depots ([@B71]). There indeed are a few reports on cold-induced browning of human perirenal fat, but whether this fat depot is a good representation of visceral fat still remains controversial ([@B11]). In the study of human patients with pheochromocytoma disease who had performed both ^18^F-fluorodeoxyglucose positron emission tomography/computed tomography (^18^F-FDG PET/CT) and plasma total metanephrine (TMN) measurements in China, browning of human visceral fat has been observed and reduces whole body fat mass by burning more fats through increased UCP1 in beige cells or BAT ([@B88]). Additionally, recent studies suggest that browning can increase the basal metabolism by burning fat through UCP1 and has been proposed as a potential approach for reducing body fat or treating obesity ([@B91]; [@B22]).

Autophagy Types in Adipocytes
-----------------------------

Adipocytes undergo three major types of autophagy: macroautophagy, macrolipophagy (generally referred as lipophagy), and mitophagy. These occur dynamically depending on browning status ([@B9]; [@B77]; [@B98]; [@B75]; [@B51]; [@B27]). Both autophagy malfunction and adipocyte dysfunction are clearly connected with the causes of metabolic disorders such as obesity and diabetes ([@B9]; [@B77]; [@B98]; [@B13]; [@B75]; [@B14]; [@B71]; [@B27]). To examine this, both mechanistic and clinical studies have investigated the significant relationship between autophagy and browning ([@B6]; [@B80]). Here, we summarize the following: 1) the three major types of autophagy and their significance in regulating adipose lipid and energy metabolism; and 2) autophagy manipulations through direct autophagy gene knockdown or chemical/drug administration affecting the browning process in humans and mice from previous publications.

Lipophagy in Adipocyte Lipid Metabolism
=======================================

Lipophagy is the selective removal of lipid droplets in cytosolic organelles by lysosomes, which are derived from stimulated autophagy markers such as LC3 and p62 ([@B75]; [@B89]). Lipogenesis, often considered identical to adipogenesis, is focused on the formation of lipid droplets during white adipocyte differentiation with autophagy activation; lipolysis, on the other hand, is the secretion of glycerol and fatty acid partially resulting from the degradation of lipid droplets by autophagy ([@B19]; [@B2]). The balance between lipogenesis and lipolysis plays a vital role in regulating the lipid metabolism in white and brown adipocytes ([@B75]; [@B57]; [@B96]). ULK1 activates lipolysis by activating autophagy in 3T3-L1 adipocytes. However, ULK1 inhibits fatty acid synthesis and uptake and activates fatty acid oxidation in the mitochondria independent of autophagy in adipocytes ([@B67]). In an *in vivo* study of POMC neurons using C57BL/6 WT mice, lipophagy in BAT and liver was activated by both cold exposure and rapamycin administration via the specific surface protein of lipid droplets, adipose triglyceride lipase (ATGL), and LC3 association ([@B57]). Although both liver and adipose tissue are important tissues in regulating lipid metabolism ([@B57]), when lipophagy was blocked in liver-specific ATG7 knockout mice, the lipid droplets accumulated in the liver and showed a steatosis-like phenotype ([@B75]; [@B52]). However, in the case of adipose-specific ATG7 knockout mice, white adipocytes showed more brown adipocyte phenotypes with decreased lipids, increased number of mitochondria and beta oxidation ([@B77]; [@B98]).

The mechanism underlying different tissue specificity is still unclear ([@B75]; [@B57]). When basal lipophagy is inhibited by hyperactivation of mTORC1 due to overnutrition in the human body, lipid droplets are rapidly accumulated in BAT and liver ([@B76]). By contrast, when inducible lipophagy is enhanced by inhibition of mTORC1 and activation of AMPK under starvation, lipophagy actively degrades lipid droplets in WAT and releases them as free fatty acids so that other metabolic tissues such as liver and muscle can utilize them as an energy source ([@B69]; [@B52]; [@B89]). Thus, the balance between basal lipophagy and inducible lipophagy, as well as the balance between lipogenesis and lipolysis, is important and seems to be a possible mechanism explaining tissue specificity. BAT and liver tissue would be more prone to the balance between the basal and inducible status of lipophagy, whereas WAT would be more prone to the balance between lipogenesis and lipolysis. These different sensitivities and availability of lipophagy according to the type of tissues and stimuli may create advantages by allowing it to quickly adapt to the different levels of nutrient status in the human body ([@B57]; [@B89]). In future studies, transgenic mice with an inducible lipophagy system may serve as a very plausible model for identifying lipophagy specificity and its effect on lipid contents depending on nutrient availability ([@B75]).

Mitophagy in Adipocyte Mitochondria Function
============================================

Mitophagy is the process of actively removing excess mitochondria through selective autophagy when mitochondria have accumulated during differentiation or have been damaged by oxidative stress such as ROS ([@B99]; [@B7]; [@B50]; [@B82]). Mitophagy can be induced by ULK1 upon AMPK activation or mTORC1 inhibition under cellular maturation or nutrient deprivation ([@B43]; [@B23]; [@B37]). The main mitophagy process, the association between mitochondria and autophagolysosomes, is mediated by the ubiquitin-dependent PINK1-Parkin pathway ([@B59]; [@B86]; [@B12]). Alternatively, mitochondria can be degraded by selective autophagy via LC3 and p62 protein independent of ubiquitin in adipose tissue ([@B4]; [@B82]; [@B55]). Mitochondria can also be degraded and decreased in number through mitophagy to form more lipid droplets in white adipocyte tissue during differentiation by limiting fatty acid oxidation ([@B29]; [@B4]). Mitophagy at least in part contributes to whitening of beige adipocytes, turning them into white adipocytes by removing mitochondria after the withdrawal of cold exposure ([@B5]; [@B4]; [@B55]). Therefore, when mitophagy is blocked in white adipocytes, mitochondria cannot be degraded and accumulated while inhibiting adipogenesis, which results in a beige/brown adipocyte phenotype ([@B4]). Consistent with cell culture studies, when mitophagy is inhibited in mice either by autophagy gene deficiency or chemical administration, WAT shows accumulation of mitochondria with decreased fat mass and changes into a phenotype like the beige or brown adipocytes ([@B75]; [@B5]; [@B82]; [@B55]). Clinical researchers have observed more accumulation of dysfunctional or metabolically impaired mitochondria in obese people compared to a lean control group ([@B42]; [@B17]). These observations possibly suggest that mitophagy would be negatively regulated by excessive fat accumulation or in obese condition. In conditions of overnutrition, mTORC1 activation and mitophagy inhibition resulted in greater accumulation of impaired mitochondria ([@B4]). Studies using autophagy-related gene knockout mice fed with a high-fat diet suggest that when autophagy and mitophagy in adipocytes are impaired by overnutrition, inhibition of lipogenesis and activation of lipophagy can occur as a compensatory mechanism ([@B98]; [@B4]). To our surprise, the browning of WAT was observed in skeletal muscle-specific Atg7 knockout mice that were resistant to obesity induced by a high-fat diet ([@B38]). This ambivalence of mitophagy in adipocyte turnover and the existence of compensation mechanisms with other selective autophagy may be for purposes of more effectively maintaining mitochondrial integrity and mass in adipocytes ([@B55]). Although mitophagy is suggested as a positive regulator of white adipogenesis and a negative regulator of beige and brown adipogenesis, the level of mitophagy necessary for browning seems controversial due to the complicated regulation of activity dependent on nutrition status ([@B4]). Therefore, the proper modulation of mitophagy in adipocytes in humans and mice seems necessary for the timely turnover between white, beige, and brown adipocytes, dependent on nutrition level.

Autophagy Manipulations in Adipocyte Browning
=============================================

Although the distribution of adipose tissue is distinct in humans and mice, both share common characteristics ([@B73]; [@B97]). Anatomically in male mice, interscapular brown adipose tissue (iBAT) contains classic brown adipocytes, whereas epididymal white adipose tissue (eWAT) and subcutaneous white adipose tissue (sWAT) contain classic white adipocytes ([@B70]; [@B29]). In humans, most classic brown adipocytes develop mainly around the neck and supraclavicular area through infancy, but gradually decrease until adulthood ([@B91]; [@B97]). Several studies using positron emission tomography (PET)-CT have demonstrated that, in addition to size reduction in aging, BAT activity is reduced in obese and diabetic patients ([@B44]; [@B45]). A few other clinical research groups have suggested that stimulating browning in WAT would be beneficial in slowing obesity, diabetes, and even the aging process ([@B71]). Therefore, the existence of active turnover from WAT to beige fat to BAT in humans and mice has been recognized as a potential therapeutic target for prevention and treatment of obesity and related metabolic diseases ([@B36]; [@B72]; [@B28]). Even whole tissue switching of WAT to BAT through surgical transplantation or implantation of mesenchymal stem cells, brown adipocytes, or BAT into WAT areas in humans and mice is gaining a new spotlight as a novel method to prevent or treat obesity and diabetes ([@B53]; [@B78]). However, the activity and selectivity of autophagy after the transplantation or implantation still needs further investigation.

Indeed, autophagy plays an important role in the browning of WAT and beige adipocytes. A recent study has reported that autophagy is needed to convert beige adipocytes to WAT upon removal of β3-AR agonists or recovery from cold exposure ([@B5]). [@B15] reported that thermogenic activation through cold exposure inhibits autophagy, which leads to increased UCP1 level in BAT. Although we have selected only a few significant factors to discuss in our review, numerous factors are involved in the manipulation of the autophagy pathway, which regulate the browning of WAT and beige adipocyte ([Table 1](#T1){ref-type="table"}).

###### 

Summary of recent studies about the effect of direct autophagy gene manipulation or autophagy-related regulators on adipocyte browning.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study            Target Gene Intervention                                                               Application                                                                                                     Results                                                                                                                                                                             Clinical/Physiological Function
  ---------------- -------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B9]; [@B77]    ATG5                                                                                   *In vitro*\                                                                                                     Chloroquine treatment and Atg5 knockdown decreased adipogenesis of MEF cells ([@B77]).\                                                                                             Chloroquine increased success in an autophagy-inhibitor based treatment therapy for a variety of cancer types in humans, when compared to chemotherapy or radiation alone ([@B93]).
                                                                                                          Chloroquine (autophagy inhibitor) treatment in MEF cells ([@B9])\                                               Perilipin A positive adipocytes in sWAT as dramatically reduced in Atg5^-/-^ late-stage embryos and neonatal pups ([@B9]).\                                                         
                                                                                                          siAtg5 (knockdown) in MEF cells ([@B77])\                                                                       Chloroquine's or Atg5's effect on browning is not observed.                                                                                                                         
                                                                                                          *In vivo*\                                                                                                                                                                                                                                                                                          
                                                                                                          Histological analysis of Atg5^-/-^ late-stage embryos and neonatal pups ([@B9])                                                                                                                                                                                                                     

  [@B77]; [@B98]   ATG7                                                                                   *In vitro*\                                                                                                     White adipocyte differentiation is blocked upon Atg7 loss, and mice showed brown adipocyte phenotypes with decreased lipids, increased number of mitochondria and beta oxidation.   N/A
                                                                                                          siAtg7 in 3T3-L1 adipocytes ([@B77])\                                                                                                                                                                                                                                                               
                                                                                                          \                                                                                                                                                                                                                                                                                                   
                                                                                                          *In vivo*\                                                                                                                                                                                                                                                                                          
                                                                                                          Adipose-specific Atg7^-/-^ and WT mice (both groups)                                                                                                                                                                                                                                                

  [@B67]           ATG1                                                                                   *In vitro*\                                                                                                     ULK1 or ULK2 is necessary for autophagy induction in adipocytes.\                                                                                                                   Rapamycin, a potent ATG1 activator through mTORC1 inhibition, has been shown to increase the rate of autophagy in ischemic adipose derived stem cells used during transplantation in humans, promoting overall success of the surgical implantation ([@B48]).
                                                                                                          Rapamycin treatment, siULK1 or siULK2 in 3T3-L1 adipocytes                                                      ULK1 negatively regulates lipogenesis independent of autophagy in adipocytes.\                                                                                                      
                                                                                                                                                                                                                          ULK1's or ULK2's effect on browning is not investigated.                                                                                                                            

  [@B57]           ATGL                                                                                   *In vivo*\                                                                                                      Both cold and rapamycin administration in POMC neuron activates lipophagy in BAT via ATGL-LC3 association.                                                                          See above
                                                                                                          Cold or rapamycin administration on C57BL/6 WT mice                                                                                                                                                                                                                                                 

  [@B15]; [@B5]    UCP1                                                                                   *In vivo*\                                                                                                      Activation of UCP1 suppresses autophagy in BAT ([@B15]).\                                                                                                                           N/A
                                                                                                          Cold administration on C57BL/6 WT mice ([@B15])\                                                                Atg5 or Atg12 knockout in beige/brown adipose tissue prevents white-like characteristics through inhibiting autophagic clearance of mitochondria ([@B5]).                           
                                                                                                          Cold or β3-AR agonist administration on \[UCP1(+)\]-adipocyte-specific Atg5 or Atg12 knockout mice ([@B5])                                                                                                                                                                                          

  [@B82]; [@B55]   PARKIN or PARK2                                                                        *In vitro*\                                                                                                     Rosiglitazone induces browning in 3T3-L1 white adipocytes; Parkin knockdown does not affect browning, but Parkin overexpression inhibits browning in adipocytes ([@B82]).\          Rosiglitazone, a PPAR-γ agonist, has been shown to increase overall body fat content in humans, but does not affect heart rate variability ([@B30]).\
                                                                                                          Rosiglitazone (browning stimuli), siParkin, or mCherry-Parkin (overexpression) in 3T3-L1 adipocytes ([@B82])\   When browning stimulus CL316243 was removed, UCP1 was reduced in WAT of WT, but was maintained in Park2 knockout mice and BAT of both groups ([@B55]).                              CL 316,243 has been shown to increase the effectiveness of insulin, and fat oxidation in lean male subjects, by acting as an agonist for β~3~-adrenergic receptor ([@B90]).
                                                                                                          *In vivo*\                                                                                                                                                                                                                                                                                          
                                                                                                          Parkin^-/-^ and WT mice with rosiglitazone or CL316243 injection ([@B82])\                                                                                                                                                                                                                          
                                                                                                          *In vivo*\                                                                                                                                                                                                                                                                                          
                                                                                                          Park2 knockout mice administered with β3-AR agonist, CL316243 ([@B55])                                                                                                                                                                                                                              

  [@B6]            Mineralocorticoid receptor antagonist: spironolactone (spiro) or drospirenone (DRSP)   *In vitro*\                                                                                                     white adipocytes, revealed by increase of brown adipose-specific markers such as UCP1 and PRDM16.                                                                                   Serum aldosterone reduction through diet change and increase in physical activity has been shown to decrease obesity-related health factors in young adults only diagnosed with excess body fat ([@B20]).
                                                                                                          3T3-L1 was differentiated with 10^-8^ M aldosterone, 10^-5^ M DRSP or 10^-5^ M spiro treatment\                                                                                                                                                                                                     
                                                                                                          *In vivo*\                                                                                                                                                                                                                                                                                          
                                                                                                          High-fat diet-fed mice with                                                                                                                                                                                                                                                                         

                                                                                                          6 mg/kg/day DRSP or 20 mg/kg/day spiro for 90 days                                                              Mineralocorticoid receptor antagonists reduced body weight gain and WAT mass gain via autophagy activation, but significantly increased browning of WAT and primary                 DRSP, an autophagy activator, currently has no human clinical trials available.\
                                                                                                                                                                                                                                                                                                                                                                                                              Spiro was shown to rescue insulin resistance in humans with chronic kidney disease, and reversed glucose intolerance in mice possibly by activating autophagy ([@B32]).

  [@B27]           PIK3C3                                                                                 *In vivo*\                                                                                                      PIK3C3 mutation led to enhanced browning of gWAT when autophagy is impaired.                                                                                                        N/A
                                                                                                          Aged C57BL/6 male mice with mutant PIK3C3 gene                                                                                                                                                                                                                                                      

  [@B62]           Thiodigalactoside (TDG)                                                                *In vitro*\                                                                                                     TDG, an inhibitor of autophagy, increases browning markers, thermogenic protein UCP1, and mitochondrial functions and activities.                                                   TDG currently has no clinical data available in humans.
                                                                                                          500 μM during 3T3-L1 and HIB1B adipocyte differentiation\                                                                                                                                                                                                                                           
                                                                                                          *In vivo*\                                                                                                                                                                                                                                                                                          
                                                                                                          5-week-old rats peritoneal injected 5 mg/kg/week for 5 weeks                                                                                                                                                                                                                                        

  [@B47]           Raspberry ketone                                                                       *In vitro*\                                                                                                     Raspberry ketone-fed rats had less adipose tissue, more browning-related markers through inhibition of autophagy.                                                                   Currently, clinical data is not available in humans for Raspberry ketone.
                                                                                                          100 μM for 48 hrs after fully differentiated 3T3-L1 adipocytes\                                                                                                                                                                                                                                     
                                                                                                          *In vivo*\                                                                                                                                                                                                                                                                                          
                                                                                                          8-week-old rats administered 160 mg/kg/day for 8 weeks                                                                                                                                                                                                                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Parkin-Mediated Mitophagy in Browning
-------------------------------------

Parkin (gene name: Park2) is a E3 ubiquitin ligase that plays a critical role in ubiquitination as a mitophagy-associated degradation signal ([@B26]; [@B34]; [@B64]). The role of Parkin in browning of WAT has been studied in 3T3-L1 adipocytes and the Parkin-deficient C57BL/6 mice model. Parkin expression increases during 3T3-L1 adipocyte differentiation, while its expression decreases in rosiglitazone-treated 3T3-L1 adipocytes, which have phenotypes of beige adipocytes due to enhanced UCP1 expression. Inhibition of the Parkin gene does not affect browning, but overexpression of Parkin significantly reduces browning in adipocytes ([@B82]). Furthermore, Parkin is highly expressed during beige adipocyte differentiation ([@B55]). The Kajimura group has shown that Parkin is required to maintain beige adipocytes in WAT. When CL316243, a β3-AR agonist, is removed, UCP1 expression is significantly reduced in WAT of wild type (WT) mice, but still expressed in WAT of Park2 knockout mice. In contrast, UCP1 expression in BAT is not changed in both WT and Park2 knockout mice after CL316243 is removed ([@B55]).

Mineralocorticoid Receptor Antagonism in Browning
-------------------------------------------------

The Yan group has shown that autophagy is regulated by mineralocorticoid receptor (MR) antagonism ([@B49]). Spironolacton induces LC3 and ATG5 expression and reduces PI3K/AKT/mTOR pathways in injured human podocytes ([@B49]). Previous research has reported the role of MR in adipocyte differentiation. Drospirenone (DRSP) significantly reduces 3T3-L1 and 3T3-F442A adipocyte differentiation without cell cytotoxicity ([@B16]). MR also regulates browning of WAT though autophagy. Additionally, it has been determined that MR antagonists fully prevent aldosterone-induced autophagy in white adipocytes along with an increase of UCP1 expression. MR antagonists significantly enhance browning of WAT in diet-induced obese mice as well as brown adipose-specific markers in primary adipocytes isolated from WAT ([@B6]).

PIK3C3 in Browning
------------------

PIK3C3 is a subunit of class III phosphoinositide 3-kindase (PI3K) that phosphorylates phosphatidylinositol to generate phosphatidylinositol 3-phosphate. The PIK3C3-ATG14 complex induces autophagy especially in nutrient-stress conditions such as starvation ([@B95]). Recently, it has been shown that in aged mice with a PIK3C3 mutation, compared to fl/fl control mice, adipogenesis markers, such as AP2 and C/EBP-α, are reduced, but brown adipose-specific markers, such as UCP1 and PPAR- γ coactivator (PGC)1α, are enhanced in both mRNA and protein levels in the gonadal WAT (gWAT), possibly through blocking of autophagy ([@B27]).

Thiodigalactoside in Browning
-----------------------------

Thiodigalactoside (TDG), an inhibitor of galectin 1 and autophagy, has recently been studied in obesity research by the Yun group ([@B58]; [@B61]; 2017). They have reported that TDG-treated adipocytes significantly inhibit lipid accumulation, and TDG also reduces body weight in high-fat diet-fed rats ([@B58]). Their second study has shown proteomic identification of TDG in WAT of rats with high-fat diet-induced obesity. Specifically, proteins involved in carbohydrate metabolism and the tricarboxylic acid cycle remarkably increased in WAT of TDG-injected obese rats ([@B61]). A most recent study has reported that TDG plays an important role in browning of white adipocytes and WAT in obese rats ([@B62]). Dose-dependent TDG treatment reduces galectin 1 and ATG 5 gene expression, but enhances brown-specific markers, UCP1 and PGC1α, in 3T3-L1 adipocytes. Moreover, UCP1 and PGC1α gene and protein expressions are upregulated by PDG injection in iWAT, eWAT, and BAT of diet-induced obese rats, possibly through inhibition of ATG5/LC3-II and increase of p62 expression ([@B62]).

Raspberry Ketone in Browning
----------------------------

Raspberry ketone, 4-(4-hydroxyphenyl) butan-2-one, a phenolic compound found in red raspberry, has emerged as a dietary bioactive compound with beneficial effects on obesity ([@B21]; [@B83]). Evidence suggests that raspberry ketone reduces body weight and food intake in high-fat diet-fed mice ([@B21]) and ovariectomy-induced obese rats ([@B46]). In addition, raspberry ketone inhibits 3T3-L1 adipogenesis, revealed by inhibition of expression of adipogenesis markers such as PPAR-γ, C/EBP-α, FAS, and AP2, possibly via inhibition of autophagy, confirmed by decrease of ATG12 and LC3B levels, as well as increase of p62 and mTORC1 levels ([@B46]; [@B83]). It has been recently reported that high concentration of raspberry ketone (100 μM) significantly increases browning of 3T3-L1 adipocytes, revealed by an increase of browning-specific markers, including UCP1 and PGC1α, and lipolysis markers such as hormone-sensitive lipase and triglyceride lipase ([@B47]). Moreover, expression of brown adipose markers is increased in ovariectomy-induced obese rats that have been administered raspberry, compared to control groups mediated by inhibition of ATG12 and an increase of p62 expression ([@B47]).

Conclusion: Autophagy- and Browning-Targeting Therapeutics for the Prevention of Obesity
========================================================================================

Adipose metabolism is closely linked with metabolic dysfunctions such as obesity and diabetes when fat distribution and energy balance through mitochondria are not strictly maintained ([@B13]; [@B14]; [@B80]; [@B71]). The relationship between adipose metabolism and autophagy has become an increasingly intriguing topic since the dawn of the discovery of selective autophagy, including lipophagy and mitophagy, which can also actively occur in adipose tissue ([@B68]). Autophagy has previously been shown to be increased in adipocytes from obese humans and mice ([@B60]; [@B41]; [@B33]). Previous reports indicate that excess free fatty acid (FFA) -- particularly saturated FFA like palmitic acid (PA), but not unsaturated FFA such as oleic acid (OA) -- formed by a high-fat diet can activate autophagy through JNK2 or PKC activation ([@B81]; [@B84]). Conversely, lipophagy seems beneficial for degrading excess fats from WAT and generating more intracellular space for the expansion of the mitochondrial contents from BAT when mitophagy is inhibited or mitochondrial biogenesis is activated, thus protecting the human body from nutrient oversupply which, can occur in obesity conditions ([@B75]; [@B22]). Mitophagy seems much more controversial because basal activity can be beneficial through elimination of damaged mitochondria from accumulated ROS in obesity; however, hyperactive inducible mitophagy can convert BAT or beige fat to white during differentiation, which is called "reverse browning or whitening," and subsequently cause systemic change in adipocytokine release and lipid metabolism ([@B31]; [@B29]). Overall, inhibition or deficiency of autophagy, activation of lipophagy rather than lipolysis, and a basal or moderate level of mitophagy seems the most optimal combination for the prevention of obesity so far ([Figure 1](#F1){ref-type="fig"}).

![Autophagy effect on adipocyte browning and potential therapeutic target for prevention of obesity. **(A)** Summary of the proposed effect of autophagy, lipophagy, and mitophagy on adipocyte browning from recent studies. LV, lipid vacuoles; M, mitochondria; N, Nucleus. **(B)** Summary of the main characteristics of WAT and BAT in obesity, and the induction of browning through manipulation of autophagy as a promising target for anti-obesity therapy.](fphys-10-00022-g001){#F1}

However, we have also encountered a few exceptional cases from previous reports noting that hyperactive autophagy can be beneficial during hypermetabolic conditions such as hepatic steatosis, atherosclerosis, injuries from burning, sepsis, and cachexia ([@B87]; [@B63]; [@B65]; [@B79]; [@B1]). Normally, hyperactivation of autophagy leads to apoptotic cell death ([@B56]), but highly autophagic cells under hypermetabolic conditions such as post-thermal injury may survive better by efficiently regulating energy metabolism ([@B8]). Paradoxically, autophagy activation in WAT can be beneficial for obese or diabetic patients with a hypermetabolic profile or complications, because it decreases FFA and glycerol release from hypertrophic and hyperplasic WAT by actively degrading lipid vacuoles (LV) as an energy source. We have summarized previously reported autophagy and selective autophagy manipulations and their effect on adipocyte browning ([Table 1](#T1){ref-type="table"}). Since the combined delicate manipulation of autophagy, lipophagy, and mitophagy seems necessary for the timely turnover between white, beige, and brown adipocytes dependent on nutrition levels in humans and mice, the direct manipulation of autophagy and selective autophagy or the administration of autophagy-targeting drugs should be cautiously performed. Finally, summarizing autophagy regulation and its implications in browning could help give insights for the development of autophagy-targeting drugs in the prevention of obesity.
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